Glenmark Pharmaceuticals Ltd. (BSE: 532296) (NSE: GLENMARK) is a research–led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic ...
Study met primary end point and demonstrated successful subcutaneous administration of a 10 mL biologic co-formulated with ENHANZE® in 30 seconds using Halozyme's proprietary high-volume auto ...
Glenmark Pharmaceuticals Ltd. (BSE: 532296) (NSE: GLENMARK) is a research–led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The new Bimzelx administration and dosage is available ...
Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce the upcoming launch1 of 8.4% Sodium Bicarbonate ...
Bard's infringement case against MedComp over injection 'access ports' reinstated MedComp also gets chance to save countersuit against Bard (Reuters) - Becton Dickinson's (BDX.N), opens new tab C.R.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results